Anticipate generic drug launch
Proactively manage your pharmacy inventory
Drug patents …
… from Kazakhstan to Kalamazoo
Manage your formulary budget
Find generic entry opportunities
Deep knowledge on
small-molecule drugs and
the 110,000 global patents
Flat-rate pricing for predictable budgeting
Short-term plans for project- or client-based billing
Upgrade to enjoy subscriber-only features like email alerts and data export. See the Plans and Pricing
|Title:||Systematic evolution of ligands by exponential enrichment: Chemi-SELEX|
|Abstract:||This application provides methods for identifying nucleic acid ligands capable of covalently interacting with targets of interest. The nucleic acids can be associated with various functional units. The method also allows for the identification of nucleic acids that have facilitating activities as measured by their ability to facilitate formation of a covalent bond between the nucleic acid, including its associated functional unit, and its target.|
|Inventor(s):||Gold; Larry (Boulder, CO), Eaton; Bruce (Boulder, CO), Smith; Drew (Boulder, CO), Wecker; Matthew (Boulder, CO), Jensen; Kirk (Boulder, CO)|
|Assignee:||NeXstar Pharmaceuticals, Inc. (Boulder, CO)|
|Filing Date:||Jun 05, 1995|
|Claims:||1. Nucleic acid ligands which bind covalently with a protein, wherein said nucleic acid ligands comprise a chemically reactive functional unit selected from the group consisting of pohotoreactive groups and active site directed compounds, wherein said nucleic acid ligands are produced by a method comprising the steps of: |
a) preparing a candidate mixture of nucleic acids;
b) contacting said candidate mixture with said protein, wherein nucleic acids which bind covalently with said protein may be partitioned from the remainder of said candidate mixture;
c) partitioning the nucleic acid-protein complexes from free nucleic acids in said candidate mixture; and
d) identifying said nucleic acid ligands that bind covalently with said protein.
2. The nucleic acid ligands of claim 1 which are selected from the sequences listed in Tables II and IV.
3. The nucleic acid ligand of claim 1 wherein said nucleic acids comprise a fixed sequence region.
4. The nucleic acid ligand of claim 3 wherein at least one fuinctional unit is attached to an oligonucleotide hybridized to said fixed sequence region.
5. A purified and non-naturally occurring nucleic acid ligand which binds covalently with a protein, wherein said nucleic acid ligand comprises a chemically reactive functional unit selected from the group comprising photoreactive groups and active site directed compounds.
Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verifification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.